Back to top

David Chatenet

Looking for students or interns

Areas of expertise

Pharmacochemistry , Medicinal chemistry , Peptide engineering , Pharmacology

Armand-Frappier Santé Biotechnologie Research Centre

531 des Prairies Blvd.
Laval, Quebec  H7V 1B7

See the research centre




*1. Merlino F, Billard E, Yousif AM, Di Maro S, Abate L,Brancaccio D,Carotenuto A,Bellavita R,d’Emmanuele di Villa Bianca R, Santicioli P, Marinelli L, Novellino E, Hébert TE,Lubell WD,Chatenet D, and Grieco P. Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. Journal of Medicinal Chemistry.

*2. Nassour H, Iddir M, Chatenet D*. Towards Targeting the Urotensinergic System: Overview and Challenges. Trends Pharmacol Sci. 2019 Sep 6. pii: S0165-6147(19)30191-9. doi: 10.1016/

*3. Lamine A, Poujol de Molliens M, Létourneau M, Hébert TE, Vaudry D, Fournier A, Chatenet D*. The amidated PACAP(1-23) fragment is a potent reduced-size neuroprotective agent. Biochim Biophys Acta Gen Subj. 2019 1863:129410.

*4. Poujol de Molliens M, Jamadagni P, Létourneau M, Devost D, Hébert TE, Patten SA, Fournier A, Chatenet D. Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate  cyclase-activating polypeptide type 1 receptor. Biochim Biophys Acta Gen Subj. 1863:129398.

5. Liao C, de Molliens MP, Schneebeli ST, Brewer M, Song G, Chatenet D, Braas KM, May V, Li J. Targeting the PAC1 Receptor for Neurological and Metabolic Disorders. Curr Top Med Chem. 2019;19(16):1399-1417.


*6. Debbabi S, Groleau MC, Létourneau M, Narayanan C,Gosselin L, Iddir M, Gagnon J, Doucet N, Déziel E* and Chatenet D. (2018) Antibacterial Properties of the Pituitary Adenylate Cyclase-Activating Polypeptide: A New Human Antimicrobial Peptide. PLOS ONE. in press.

*7. Billard E, Iddir M, Nassour H, Lee-Gosselin L, Poujol de Molliens M, Chatenet D. (2018) New directions for urotensin II receptor ligands. Peptide Science.

*8. Billard E, Hébert TE, Chatenet D. (2018) Discovery of new allosteric modulators of the urotensinergic system through substitution of the URP phenylalanine residue. J. Med. Chem. 2018 Oct 11;61(19):8707-8716.


9*. Poujol de Molliens M, Létourneau M, Devost D, Hébert TE, Fournier A, Chatenet D. New insights about the peculiar role of the 28-38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection.Biochem. Pharmacol. 154:193-202.


*10. Douchez A, Billard E, Hébert TE, Chatenet D, Lubell WD. Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics.J Med Chem. 2017 60(23):9838-9859.

*11. Billard E, Létourneau M, Hébert TE, Chatenet D. (2017) Insight into the role of urotensin II-related peptide tyrosine residue in UT activation.Biochem. Pharmacol.doi: 10.1016/j.bcp.2017.08.003.

12. Strack M, Billard EChatenet D, Lubell WD. (2017) Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II.Bioorg. Med. Chem. Lett.2017 Aug 1;27(15):3412-3416.

*13. Chatenet D, Hébert TE. (2017) Understanding GPCR signaling in the brain- the path to CNS drug discovery.Curr. Opin. Pharmacol. 32, v-vii.

14. Tadevosyan A, Xiao J, Surinkaew S, Naud P, Merlen C, Harada M, Qi X, Chatenet D, Fournier A, Allen BG, Nattel S. (2017) Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion.J. Am. Heart Assoc.doi: 10.1161/JAHA.116.004965.

15. Thamri A, Létourneau M, Djoboulian A, Chatenet D, Déziel E, Castonguay A, Perreault J. (2017) Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity.PLoS One. doi: 10.1371/journal.pone.0173783.


*16. Lamine A, Létourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A. (2016) Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity  and reduced in vivo cardiovascular side effects in a Parkinson’s disease model. Neuropharmacology 108, 440-450.

17. Tadevosyan A, Villeneuve LR, Fournier A, Chatenet D, Nattel S, Allen BG. (2016) Caged Ligands to Study the Role of Intracellular GPCRs. Methods 92, 72-77.

18. Lamine-Ajili A, Fahmy AM, Létourneau M, Chatenet D, Labonté P, Vaudry D, Fournier A. (2016) Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson’s disease. Biochim Biophys Acta. 1862, 688-95.

*19. Merlino F, Yousif AM, Billard E, Dufour-Gallant J, Turcotte S, P. Grieco, D. Chatenet D, Lubell WD. (2016) Urotensin II(4-11) Azasulfuryl Peptides: Synthesis and Biological Activity. J Med Chem 59, 4740-4752.


20. Vladoiu MC, Labrie M, Létourneau M, Egesborg P, Gagné D, Billard E, Grosset AA, Doucet N, Chatenet D, St-Pierre Y.(2015) Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. Oncotarget. 38, 40970-40980

*21. Doan ND,Poujol de Molliens M, Létourneau M, Fournier A, Chatenet D. Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in astructure-activity relationship study of a class B GPCR ligand. Eur. J. Med. Chem 104, 106-114

22. Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mevel JC, Ohlstein O, Schwertani A, Tostivint H, Vaudry D. Urotensin II, Urotensin II-Related Peptide and their Receptor: from Structure to Function. Pharmacol Rev. 67(1), 214-258.

*23. Dufour Gallant J,Chatenet D, Lubell W. De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo. J Med Chem. 58(11), 4624-4637.

*24.Chatenet D, Bourgault S, Fournier A. Design and application of light-activated probes for cellular signaling. Methods in Molecular Biology. 1234, 17-30.

25. Tadevosyan A, Létourneau M, Folch B, Doucet N, Villeneuve LR, Mamarbachi AM, Hébert TE, Fournier A, Chatenet D, Allen BG, Nattel S. Photo-Releasable Ligands to Study Intracrine Angiotensin II Pharmacology. J Physiol. 593(3), 521-39.


26. Tchoumi Neree A, Nguyen PT, Chatenet D, Fournier A, Bourgault S. Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP. FEBS Lett. 588, 4590-4596.

*27. Nguyen TTN, Folch B, Létourneau M, Truong NH, Doucet N, Fournier A, Chatenet D. (2014) Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity. J. Med. Chem. 57, 2623-2633.

Publications in collective works and book chapters

  1. Curent Opinion in Pharmacology, Neursociences, volume 32, Edited by David Chatenet and Terence E. Hébert.
  1. D. Vaudry, D. Burel, L. Galas, H. Lacaille, D. Duterte-Boucher, D. Chatenet, A. Fournier, H. Vaudry. PACAP. (2013) In A. J. Kastin (Ed.) Handbook of biologically active peptides. London: Academic.
  1. D. Chatenet, A. Fournier, S. Bourgault. (2016) PACAP-derived carriers: mechanisms and applications. In: Reglodi D., Tamas A. (eds) Pituitary Adenylate Cyclase Activating Polypeptide — PACAP. Current Topics in Neurotoxicity, vol 11. Springer, Cham.

A. Fournier, S. Bourgault, D. Chatenet. (2016) The pharmacophoric determinants of PACAP. In: Reglodi D., Tamas A. (eds) Pituitary Adenylate Cyclase Activating Polypeptide — PACAP. Current Topics in Neurotoxicity, vol 11. Springer, Cham.